论文部分内容阅读
目的探讨曲美他嗪治疗尿毒症性心肌病患者的临床疗效。方法选取2013年6月至2015年1月沈阳市第一人民医院收治的68例尿毒症性心肌病患者为研究对象,按就诊顺序将其分为观察组和对照组,各34例。对照组患者给予常规治疗,观察组患者在对照组基础上口服曲美他嗪,比较两组患者的治疗效果、治疗前后心功能改善情况。结果观察组患者的总有效率明显高于对照组,差异有统计学意义(P<0.05);治疗后,观察组患者的左心房内径(LAD)、左心室收缩末期内径(LVESd)、左心室舒张末期内径(LVEDd)、室间隔厚度(IVST)、左心室后壁厚度(LVPET)均明显低于对照组,左心室射血分数(LVEF)、舒张早期最大血流速度/舒张晚期最大血流速度(E/A)均明显高于对照组,差异均有统计学意义(均P<0.05)。结论曲美他嗪治疗尿毒症性心肌病患者临床疗效明显,可明显改善患者的心功能。
Objective To investigate the clinical efficacy of trimetazidine in patients with uremic cardiomyopathy. Methods Sixty-eight patients with uremic cardiomyopathy who were admitted to Shenyang First People’s Hospital from June 2013 to January 2015 were selected as study subjects and divided into observation group and control group according to the order of treatment, 34 cases in each group. The patients in the control group were given routine treatment. The patients in the observation group were given trimetazidine orally on the basis of the control group, and the treatment effect was compared between the two groups. The improvement of cardiac function before and after treatment was compared. Results The total effective rate of the observation group was significantly higher than that of the control group (P <0.05). After treatment, the left atrium diameter (LAD), left ventricular end-systolic diameter (LVESd) LVEDd, IVST and LVPET were significantly lower than those in the control group, left ventricular ejection fraction (LVEF), maximal diastolic flow velocity / maximal diastolic flow velocity Speed (E / A) were significantly higher than the control group, the difference was statistically significant (P <0.05). Conclusion Trimetazidine treatment of uremic cardiomyopathy patients with significant clinical efficacy, can significantly improve the patient’s cardiac function.